Boosh Plant Based Brands

CASSAVA SCIENCES (NASDAQ: SAVA) STOCK QUOTE

Last Trade: US$26.51 -1.61 -5.73
Volume: 736,444
5-Day Change: -13.93%
YTD Change: -39.34%
Market Cap: US$1.060B

LATEST NEWS FROM CASSAVA SCIENCES

$209.7 Million Cash and Cash Equivalents at March 31, 2022 Over 120 Patients Now Enrolled in Phase 3 Program Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’... Read More
Q&A Session at Conference on Wednesday, April 27 th at 1:30PM Eastern Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022. Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley... Read More
All Stakeholder Are Welcome to Listen by Webcast Event To Be Held Tuesday, April 5 th , 9am ET Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for an upcoming, previously announced presentation and fireside chat with Remi Barbier, President & CEO and Eric Schoen, Chief Financial Officer. This event is scheduled to take place on... Read More
CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates Stakeholders Are Invited to Submit Questions via Email Fireside Chat Will Be Open to The Public via Webcast Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, its President & CEO, will discuss clinical and corporate updates for Q1 2022 in a fireside chat and... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates. “In second half 2021, we initiated two separate Phase 3 clinical studies with our lead drug candidate, simufilam, in patients with Alzheimer’s disease,” said Remi Barbier, President & CEO. “This was a... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and Drug Administration ("FDA") denied a Citizen Petition that was filed in August 2021 by an attorney on behalf of short-selling clients. FDA also denied four supplements to the August 2021 Citizen Petition. FDA also denied a September 2021 Citizen Petition, and a supplement, that... Read More
New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants. Rethink-ALZ.com connects patients with nearest participating clinical site. Phase 3 efficacy studies now in over 25 clinical sites across the country. Cassava Sciences, Inc. , (NASDAQ: SAVA) a biotechnology company, today announced the launch of a new clinical website, called www.Rethink-ALZ.com.... Read More
Editor-in-Chief States: “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication.” Clearance Is From A Neutral Party Who Is Expert In The Field Cassava Sciences, Inc. , (Nasdaq: SAVA) a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease. This second Phase 3 study is designed to evaluate the safety and efficacy of simufilam over 78 weeks in approximately 1,000 patients with Alzheimer’s disease across clinical sites in the U.S. and Canada. “Alzheimer’s... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2021. Net loss for the third quarter ended September 30, 2021, was $9.6 million, or $0.24 per share, compared to a net loss of $1.4 million, or $0.06 per share, for the same period in 2020. Net cash used in operations was $22.2 million during... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA) has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012 describing a new approach to treating Alzheimer's disease 1 . The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company’s lead drug candidate for the proposed... Read More
First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s Disease A Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate Simufilam Over 78 Weeks In 1,000 Patients with Alzheimer’s Disease Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today it has initiated an initial Phase 3 efficacy... Read More
Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001) Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12 No Behavior Disorders on NPI in Over 50% Of Study Subjects at Month 12 Initiation of Pivotal Phase 3 Clinical Program Remains On-track for Q4 2021, with Special Protocol Assessments from FDA Cassava Sciences, Inc. (Nasdaq: SAVA) announced top-line clinical... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present at H.C. Wainwright’s 23 rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021. Cassava Sciences’ presentation is a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C.... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a public statement regarding recent allegations made against the Company. “Let me be very clear: I think these allegations are false,” said Remi Barbier, President & CEO. “The allegations claim our science is improbable, unexpected and unique to Cassava Sciences, and therefore it’s all an elaborate fraud. By these... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer’s disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples. The... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted on-line yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 studies of oral simufilam for the treatment of patients with Alzheimer’s disease. These SPA agreements document that FDA has reviewed and agreed upon the key design... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2021. Net loss for the second quarter ended June 30, 2021, was $5.1 million, or $0.13 per share, compared to a net loss of $1.1 million, or $0.05 per share, for the same period in 2020. Net cash used in operations was $7.4 million during the... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call. Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Company’s growth strategy. The... Read More
Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 Months Cognition Improved 3.0 Points on ADAS-Cog at 9 Months ( p<0.001) Cognitive Improvements Track with Biomarker Improvements No Behavior Disorders in Over 50% of Patients No Safety Issues Improvements in Cognition, Biomarkers and Behavior Suggest Highly Encouraging Treatment Effects Oral Presentation at... Read More
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam Treatment Simufilam 100 mg and 50 mg Reduced Plasma Levels of Altered Filamin A in Alzheimer’s Patients 48% (p=0.003) and 44% (p=0.02) Respectively Plasma Results with SavaDx Track Plasma Results with p-Tau181 Plasma Data Provide Evidence of Target Engagement Poster Presentation at AAIC... Read More
On Monday, July 26 th , New Clinical Data for SavaDx to be Shared in a Poster Presentation On Thursday, July 29 th , New Clinical Data for Simufilam to be Featured in a Podium Presentation Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it will present two new clinical datasets for its product candidates at the 2021 Alzheimer’s Association International... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the selection of Premier Research International as its clinical research organization (CRO) to help conduct the Phase 3 clinical program of simufilam for Alzheimer’s disease. Consistent with previous guidance, Cassava Sciences plans to initiate this Phase 3 program in the second half of 2021. “Having completed over... Read More
Open-label Study Completes Patient Enrollment Cognition Maintenance Study Initiated May 2020, now 30% Enrolled 6-month Biomarker Data to be Presented at AAIC Conference in July 9-month Safety & Cognition Data to be Presented at AAIC Conference Clinical Results with SavaDx to be Presented at AAIC Conference Phase 3 Program Initiation Remains On-track for 2 nd Half 2021 Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021. Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will present a corporate overview on Tuesday, June 22 nd at 3:20pm Eastern time.... Read More
Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of Mr. Richard (Rick) Barry to the Company’s Board of Directors, effective June 11, 2021. “We’re very pleased to add Rick Barry as an independent director,” said Remi... Read More
Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time Discussion to be Moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it will participate in a Q&A panel discussion focused on innovative treatment approaches for Alzheimer’s disease. Jason McCarthy,... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been awarded a new $2.7 million research grant award from the National Institutes of Health (NIH). This research grant is intended to fund clinical readiness activities in support of Cassava Sciences’ upcoming Phase 3 program with simufilam, its drug candidate for Alzheimer’s disease. "We... Read More
Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months Target Enrollment is 100 Study Participants Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease. Simufilam... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 28-29, 2021. The B. Riley Securities' Neuroscience Conference will cover key topics across neurodegeneration and neuropsychiatry disease areas with leading companies in... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the Sachs 4 th Annual Neuroscience Innovation Forum, a virtual event held on April 28-30, 2021. The National Institute on Aging of the National Institutes of Health (NIH) has invited Cassava Sciences to showcase its scientific program at this event. Lindsay... Read More
9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation Initiation of Pivotal Phase 3 Program Remains On-track for 2 nd Half 2021 Initiation of Cognition Maintenance Study On-track for June 2021 Cash and cash equivalents were $282.2 million at March 31, 2021 Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2020 and provided business updates. Unaudited cash and cash equivalents were approximately $280 million as of February 2021. “In Q1 2021 we announced that our lead drug candidate, simufilam, improved cognition scores in 50 patients with Alzheimer’s... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. “I am pleased with... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the H.C. Wainwright Global Life Sciences Conference, a virtual event being held Tuesday, March 9 th , and Wednesday, March 10 th , 2021. Management is scheduled to present and will participate in virtual one-on-one meetings with institutional analysts and... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference. Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, are scheduled to present on Thursday, February 25 th at 2:20pm Eastern time and will participate in virtual one-on-one meetings with... Read More
{youtube}https://www.youtube.com/watch?v=nDjwToc428c{/youtube} Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 Program Support a New Drug Application Filing for Simufilam in Alzheimer’s disease Agreement Reached to Use ADAS-Cog as Co-Primary Efficacy Endpoint Pivotal Phase 3 Program Remains On-track to be Initiated 2 nd Half 2021 Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company developing... Read More
Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS